DBV712（花生贴片）经皮免疫治疗花生过敏的安全性和有效性。
Safety and efficacy of epicutaneous immunotherapy with DBV712 (peanut patch) in peanut allergy.
机构信息
Pediatric Gastroenterology Department, Marcel Sembat Clinic, Ramsay Group, Boulogne Billancourt, France.
Division of Pediatric Allergy and Immunology, Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
出版信息
Expert Rev Clin Immunol. 2024 Jun;20(6):623-633. doi: 10.1080/1744666X.2024.2315221. Epub 2024 Feb 14.
INTRODUCTION
DBV712 250 µg (also referred to as Viaskin Peanut or peanut patch; Viaskin is a trademark of DBV Technologies) is an innovative approach to epicutaneous immunotherapy (EPIT). The patch-based technology system facilitates peanut protein (allergen) absorption into the intact non-vascularized epidermis to promote desensitization to peanut while limiting systemic allergen exposure.
AREAS COVERED
Efficacy and safety in children have been evaluated in four completed phase 3 studies. Overall, the results from these studies have demonstrated the peanut patch to be superior in desensitization compared with placebo and safe for daily use over multiple years.
EXPERT OPINION
These findings, as well as supportive evidence from phase 2 studies, confirm the potential for an effective treatment of peanut allergy in children. The purpose of this review is to summarize the safety and efficacy of the peanut patch in the treatment of peanut allergy.
简介
DBV712 250µg（也称为 Viaskin 花生或花生贴片；Viaskin 是 DBV 技术公司的商标）是一种针对经皮免疫治疗（EPIT）的创新方法。基于贴片的技术系统有助于将花生蛋白（过敏原）吸收到完整的非血管化表皮中，以促进对花生的脱敏，同时限制全身过敏原暴露。
涵盖领域
在四项已完成的 3 期研究中评估了儿童的疗效和安全性。总体而言，这些研究的结果表明，与安慰剂相比，花生贴片在脱敏方面更有效，并且可以安全使用多年。
专家意见
这些发现以及来自 2 期研究的支持证据证实了在儿童中有效治疗花生过敏的潜力。本综述的目的是总结花生贴片治疗花生过敏的安全性和有效性。
Zotero 插件